Bausch & Lomb, Arrow shareholders approve buy-out offers:
This article was originally published in Clinica
Executive Summary
Warburg Pincus has won over Bausch & Lomb's shareholders, who last week approved the private equity firm's $65-per-share all cash offer to buy the eye care company. Over two thirds of the total shares were voted in favour of the transaction, which is expected to close early in the fourth quarter of 2007. Another merger deal poised to close is Teleflex's $2bn acquisition of Arrow International. Arrow shareholders gave their blessing to the transaction, and voted to re-elect all of Arrow's existing board directors. The deal is slated to close on October 1.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.